Since we have shown that MUS81 deficiency and XPF deficiency are both associated with sensitivity to oxaliplatin chemotherapy, it is reasonable to speculate that cells within a tumor that have high expression of MUS81 or XPF will have a greater chance to clonally evolve and to survive through treatment. Here, MUS81 is linked to neoplasm.